Trial Profile
Phase II Study to Evaluate Efficacy of Rechallenge With Sunitinib in Patients With Metastatic Pancreatic Neuroendocrine Tumor (pNETs) Well Differentiated G1/2 Advanced or Metastatic Who Previously Failed to Sunitinib
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Endocrine gland neoplasms; Neuroendocrine tumours; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms GETNE; RESUNET
- 21 Sep 2020 Status has been changed to discontinued as per results presented at the 45th European Society for Medical Oncology Congress.
- 21 Sep 2020 Results presented at the 45th European Society for Medical Oncology Congress
- 03 Mar 2020 Status changed from active, no longer recruiting to completed.